Seelos Therapeutics Inc
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more
Market Cap & Net Worth: Seelos Therapeutics Inc (SEEL)
Seelos Therapeutics Inc (OTCQB:SEEL) has a market capitalization of $226.59K ($226.59K) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #40180 globally and #13050 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seelos Therapeutics Inc's stock price $0.39 by its total outstanding shares 581000 (581.00K).
Seelos Therapeutics Inc Market Cap History: 2015 to 2024
Seelos Therapeutics Inc's market capitalization history from 2015 to 2024. Data shows change from $581.00 Billion to $226.59K (-80.28% CAGR).
Seelos Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seelos Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
46.92x
Seelos Therapeutics Inc's market cap is 46.92 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $581.00 Billion | $4.84 Million | -$19.02 Million | 120066.13x | N/A |
| 2016 | $87.01 Billion | $5.76 Million | -$7.43 Million | 15098.17x | N/A |
| 2019 | $2.99 Billion | $375.00K | -$50.38 Million | 7972.26x | N/A |
| 2020 | $3.53 Billion | $375.00K | -$19.22 Million | 9400.12x | N/A |
| 2022 | $1.51 Billion | $808.00K | -$76.14 Million | 1874.85x | N/A |
| 2023 | $103.37 Million | $2.20 Million | -$37.88 Million | 46.92x | N/A |
Competitor Companies of SEEL by Market Capitalization
Companies near Seelos Therapeutics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Seelos Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Seelos Therapeutics Inc Historical Marketcap From 2015 to 2024
Between 2015 and today, Seelos Therapeutics Inc's market cap moved from $581.00 Billion to $ 226.59K, with a yearly change of -80.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $226.59K | -99.78% |
| 2023 | $103.37 Million | -93.18% |
| 2022 | $1.51 Billion | -58.34% |
| 2021 | $3.64 Billion | +3.16% |
| 2020 | $3.53 Billion | +17.91% |
| 2019 | $2.99 Billion | -76.74% |
| 2018 | $12.85 Billion | -89.57% |
| 2017 | $123.15 Billion | +41.54% |
| 2016 | $87.01 Billion | -85.02% |
| 2015 | $581.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 17th, 2025 the market cap of Seelos Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $226.59K USD |
| MoneyControl | $226.59K USD |
| MarketWatch | $226.59K USD |
| marketcap.company | $226.59K USD |
| Reuters | $226.59K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.